Mass Spectrometry is key technology for studying critical molecules and pathways. Defining molecular targets is crucial for the process of drug development.
In our group, we are focused on using proteomics, mass spectrometry and biochemical approaches to understand disease processes.
Proteomics and Mass Spectrometry
The group has expertise in proteomics based methodologies and hosts a platform containing a variety of chromatography equipment and mass spectrometers.
We apply mass spectrometry to discover "molecular windows" of human diseases to accelerate target discovery.
- For Non-Scientists
- Research Overview
- Mass Spectrometry
- Publications 2022
- Publications 2021
- Publications 2020
- Publications 2019
- Publications 2018
- Publications 2017
- Publications 2016
- Publications 2015
- Publications 2014
- Publications 2013
- Publications 2012
- Publications 2011
- Publications 2010
- Publications 2009
- Publications 2005-2008
- Publications 2001-2004
- Publications 1997-2000
- Public Engagement
- Photo Gallery
- Virtual tour of the Kessler Lab
- Former Group Members
Accessory ESCRT-III proteins are conserved and selective regulators of Rab11a-exosome formation.
Marie PP. et al, (2023), J Extracell Vesicles, 12
Structural basis for SMAC-mediated antagonism of caspase inhibition by the giant ubiquitin ligase BIRC6
Dietz L. et al, (2023), Science
Activity-Based Protein Profiling (ABPP) for Cellular Deubiquitinase (DUB) and Inhibitor Profiling at Deep and High-Throughput Levels.
Jones HBL. et al, (2023), Methods in molecular biology (Clifton, N.J.), 2591, 101 - 122
Nilabh Shastri – Towards understanding classical and non-classical MHC-I antigen processing and presentation
Kessler BM., (2022), Cellular Immunology, 382, 104638 - 104638
T-cell trans-synaptic vesicles are distinct and carry greater effector content than constitutive extracellular vesicles
Céspedes PF. et al, (2022), Nature Communications, 13